<DOC>
	<DOCNO>NCT02267356</DOCNO>
	<brief_summary>VT-1161 novel , oral inhibitor fungal lanosterol demethylase ( CYP51 ) . In vitro vivo pharmacology study demonstrate VT-1161 highly active dermatophytes cause onychomycosis . VT-1161 highly selective fungal CYP51 , data suggests may avoid side-effect profile limit use commonly prescribed antifungal agent treatment onychomycosis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Oral VT-1161 Patients With Onychomycosis Toenail</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<criteria>Key Distal subungual onychomycosis great toenail , affect least ≥25 ≤75 % nail . Positive culture dermatophytes positive KOH . Nail ≤ 3 mm thick distal end . At least ≥ 2 mm proximal end great toenail must free infection . Subjects must able swallow tablet . Women childbearing potential male must use acceptable birth control method throughout study . Key Presence subungual hematoma melanonychia . Presence dermatophytoma/nail streak severe onychorrhexis . Significant dystrophy anatomic abnormality great toenail . Presence infection foot . Evidence clinically significant major organ disease . Poorly control diabetes mellitus . Onychomycosis involve 8 toe nail . Recent use systemic antifungal therapy . Recent topical antifungal nail therapy . Recent use systemic corticosteroid therapy . Recent use immunosuppressive medication . History prolong QT interval . Known human immunodeficiency virus ( HIV ) infection . Known significant renal hepatic impairment . Known history intolerance hypersensitivity azole antifungal drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>